Thomas Steyer Farallon Capital Management
Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$418M |
| 2 |
Alphabet (Google) Class C
GOOG
|
+$235M |
| 3 |
Exelixis
EXEL
|
+$219M |
| 4 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$191M |
| 5 |
SJR
Shaw Communications Inc.
SJR
|
+$183M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$152M |
| 2 |
Clarivate
CLVT
|
+$127M |
| 3 |
SGFY
Signify Health, Inc.
SGFY
|
+$113M |
| 4 |
LHCG
LHC Group LLC
LHCG
|
+$111M |
| 5 |
ATVI
Activision Blizzard
ATVI
|
+$87M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 33.33% |
| 2 | Technology | 18.46% |
| 3 | Financials | 12.48% |
| 4 | Industrials | 7.09% |
| 5 | Communication Services | 7.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Inspire Medical Systems
INSP
$1.8B
| $56.8M | 0.31% |
242,596
| – | – |
|
52
Agios Pharmaceuticals
AGIO
$1.98B
| $48.1M | 0.26% |
2,092,829
+67,000
| +3% | +$1.78M |
|
53
Silicon Motion
SIMO
$8.76B
| $46.2M | 0.25% |
705,000
-226,510
| -24% | -$14.9M |
|
|
SGEN
54
DELISTED
Seagen Inc. Common Stock
SGEN
| $45.6M | 0.25% |
+225,000
| New | +$36.1M |
|
55
Tower Semiconductor
TSEM
$25.2B
| $41.4M | 0.23% |
975,000
-640,000
| -40% | -$26.7M |
|
56
HCA Healthcare
HCA
$92.9B
| $41.3M | 0.23% |
+156,600
| New | +$39.8M |
|
57
Madrigal Pharmaceuticals
MDGL
$11.9B
| $39.7M | 0.22% |
163,819
+10,819
| +7% | +$2.95M |
|
58
Bruker
BRKR
$9.07B
| $39M | 0.21% |
494,476
-364,824
| -42% | -$26.3M |
|
59
Evolent Health
EVH
$536M
| $37.1M | 0.2% |
1,143,909
+841,909
| +279% | +$26.6M |
|
60
Natera
NTRA
$47.9B
| $36.7M | 0.2% |
661,783
+518,583
| +362% | +$24.9M |
|
61
Cytokinetics
CYTK
$10.7B
| $33M | 0.18% |
938,072
-763,666
| -45% | -$31.2M |
|
|
RETA
62
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $29.5M | 0.16% |
325,000
-7,000
| -2% | -$411K |
|
|
KVSC
63
DELISTED
Khosla Ventures Acquisition Co. III Class A Common Stock
KVSC
| $28.5M | 0.16% |
2,809,000
| – | – |
|
|
MTAL
64
DELISTED
Metals Acquisition
MTAL
| $25.4M | 0.14% |
2,489,700
| – | – |
|
|
BACA
65
DELISTED
Berenson Acquisition Corp. I
BACA
| $24.9M | 0.14% |
2,475,000
| – | – |
|
66
Tenet Healthcare
THC
$22.6B
| $23.1M | 0.13% |
+389,000
| New | +$21.6M |
|
67
Jazz Pharmaceuticals
JAZZ
$16.5B
| $21.9M | 0.12% |
150,000
-79,800
| -35% | -$11.8M |
|
68
Savara
SVRA
$1.15B
| $21.3M | 0.12% |
10,908,086
+773,125
| +8% | +$1.74M |
|
|
APLS
69
DELISTED
Apellis Pharmaceuticals
APLS
| $20.9M | 0.11% |
317,553
-132,847
| -29% | -$7.67M |
|
|
MAXR
70
DELISTED
Maxar Technologies Inc. Common Stock
MAXR
| $20.4M | 0.11% |
+400,000
| New | +$20.5M |
|
|
IVCP
71
DELISTED
Swiftmerge Acquisition Corp. Class A Ordinary Share
IVCP
| $20.4M | 0.11% |
1,980,000
| – | – |
|
72
Zymeworks
ZYME
$2.05B
| $18.1M | 0.1% |
2,000,000
+500,000
| +33% | +$4.36M |
|
|
SEDA
73
DELISTED
SDCL EDGE Acquisition Corporation
SEDA
| $17.8M | 0.1% |
1,732,500
| – | – |
|
74
BioNTech
BNTX
$29.3B
| $17.1M | 0.09% |
137,644
-2,356
| -2% | -$323K |
|
|
SYNH
75
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $16.8M | 0.09% |
+472,000
| New | +$17.1M |
|
Similar funds
Thomas Steyer's Q1 2023 Portfolio in Review
As of Q1 2023, Thomas Steyer held 256 positions worth $18.3B, up 8.2% from $16.9B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Thomas Steyer withdrew a net $639M in Q1 2023, closing 63 positions and reducing 47 holdings. Its most notable exit was AbbVie, an estimated $152M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 33% of assets, up from 32% a quarter earlier, followed by Technology and Financials.
Against the trend, Thomas Steyer opened a new position in UnitedHealth worth $409M.
- Thomas Steyer's largest Q1 2023 buy was UnitedHealth: 866,000 shares worth $409M.
- Thomas Steyer added most to Alphabet (Google) Class C in Q1 2023, an estimated $235M increase.
- Thomas Steyer's biggest Q1 2023 reduction was Activision Blizzard, cutting an estimated $87M.
- Thomas Steyer fully exited AbbVie in Q1 2023, selling an estimated $152M.
- Thomas Steyer's ten largest holdings make up 38% of its $18.3B portfolio in Q1 2023.
- Thomas Steyer opened 14 new positions and closed 63 in Q1 2023.
- Thomas Steyer's portfolio value rose 8.2% quarter-over-quarter to $18.3B.
Based on Farallon Capital Management's 13F filing for Q1 2023, filed 15 May 2023.